Atai and Recognify's schizophrenia drug fails to meet main goal in trial – Reuters

Written by

admin

in

  1. Atai and Recognify’s schizophrenia drug fails to meet main goal in trial  Reuters
  2. Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia  Yahoo Finance
  3. Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial  TradingView
  4. Canaccord Increases Atai Life Sciences (ATAI) PT, Keeps Buy Rating  Insider Monkey
  5. atai Life Sciences poised to lead treatment-resistant depression market with psychedelic candidate  Proactive financial news

Continue Reading

More posts